What type of study is this?

This is a Literature Review study.

September 12, 2025Open Access

Dexmedetomidine in Neonatal Sedation and Analgesia: A Literature Review

Key Points

Dexmedetomidine can effectively reduce opioid exposure in neonatal intensive care settings, but careful monitoring is essential.
Emerging data suggest potential benefits in safety and efficacy of dexmedetomidine during therapeutic hypothermia for neonates with hypoxic–ischemic encephalopathy.
Bradycardia is the primary adverse event associated with dexmedetomidine use, necessitating careful dose management in vulnerable populations.
The lack of robust randomized trials highlights the need for further research to establish long-term safety and comparative effectiveness.

Abstract

Introduction: Dexmedetomidine, a selective alpha-2 adrenergic agonist, is increasingly used off-label in neonatal intensive care for sedation and analgesia given its minimal respiratory depressant effects and potential opioid-sparing properties. Despite growing utilization, high-grade evidence in neonates—especially during therapeutic hypothermia for hypoxic–ischemic encephalopathy and in extremely preterm infants—remains limited, and safety concerns such as bradycardia require careful monitoring. This review synthesizes recent clinical and pharmacologic data to inform specialist practice. Objective: To summarize contemporary evidence on dexmedetomidine for neonatal sedation and analgesia, appraise efficacy and safety across key neonatal subpopulations, and identify gaps to guide future trials. Methods: A narrative review of studies published from 2020 onward was conducted using PubMed, Scopus, Web of Science, Cochrane Library, and Google Scholar. Eligible sources included randomized and nonrandomized clinical studies, pharmacokinetic analyses, quality improvement reports, and evidence syntheses in English focused on neonates or including neonatal subgroups. Results and Discussion: Observational and implementation studies suggest dexmedetomidine can reduce exposure to opioids and benzodiazepines in several NICU contexts and is feasible during therapeutic hypothermia, although bradycardia is the principal adverse event and pharmacokinetics are altered by asphyxia and cooling. Data on neurodevelopment and feeding outcomes are emerging, but the evidence base lacks adequately powered randomized trials and robust long-term safety assessments. Conclusion: Dexmedetomidine is a promising adjunct or alternative to traditional sedatives in neonatal care, particularly when respiratory stability and opioid minimization are priorities, yet definitive comparative effectiveness and long-term safety data are still needed. Clinicians should employ structured protocols, vigilant hemodynamic monitoring, and dose individualization, while the field prioritizes randomized trials with harmonized outcomes and long-term follow-up. Descriptors: Dexmedetomidine, Infant, Newborn, Hypothermia, Induced, Analgesia

Dexmedetomidine in Neonatal Sedation and Analgesia: A Literature Review

Key Points

Abstract

Cite This Study

Also Consider

Also Consider